Entity > Corporation > US > New York City New York > Pulmatrix

About Pulmatrix

Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology.

Pulmatrix Discovers and Develops iSPERSE: Pulmatrix discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States.

Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE™ (inhaled Small Particles Easily Respirable and Emitted), which enables the delivery of small or large molecules to the lungs by inhalation for local or systemic applications. The iSPERSE™ powders are designed as small, dense particles with highly efficient dispersibility and delivery to the respiratory tract. iSPERSE™ powders can be used with a range of dry powder inhalation technologies and formulated with a wide range of drugs including small molecules and biologics.

Partnering with Pharmaceutical Companies: Pulmatrix partners with India's second largest pharmaceutical company, Cipla, for the Pulmazole™ antifungal program for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA), with Nocion Therapeutics to explore new technologies to enable and improve inhaled drug delivery, and with Sensory Cloud to develop and commercialize a potential nasal prophylaxis and anti-contagion product for COVID -19.

Pulmatrix Mission Prioritizes iSPERSE Technology: Pulmatrix is committed to developing and commercialising novel and transformational medicines for patients around the world. In doing so, the company uses its proprietary iSPERSE™ technology to optimally deliver both respiratory and non-respiratory therapies through the respiratory system.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Pulmatrix